Citius Pharmaceuticals is trading 11.9% up at $0.64, outperforming the broader market as healthcare stocks rally, with added support from a rebound after the sharp August 17 decline.
- No major company-specific announcement dated August 19, 2026 was identified.
- The latest material catalyst remains the August 14 fiscal third-quarter update, which showed LYMPHIR revenue growth but highlighted limited liquidity and an expected cash runway through November.
- Confidence is medium because no direct company-specific explanation was reported.